E-DRUG Archives (by date)

• Thread Index

October 31, 2001
• [e-drug] Patents, Commodities...
  • From: Bonnie Fundafunda <bfunda@echohealth.org.uk>
• [e-drug] NYTimes: The Urgency of Cheaper Drugs
  • From: E-drug <e-drug@usa.healthnet.org>
• [e-drug] MSF DOHA Briefing Document
  • From: "Ellen 't Hoen" <ellen.t.hoen@paris.msf.org>
October 30, 2001
• [e-drug] USA Today: Cipro and how drugmakers protect profits
  • From: E-drug <e-drug@usa.healthnet.org>
• [e-drug] Japan drug formulary (cont'd)
  • From: Hank Malinowski <malinowski@cder.fda.gov>
• [e-drug] Health and 'commodities' (cont'd)
  • From: Rich Mahoney <rmahoney@ivi.int>
• [e-drug] Doxycycline becomes D.C.'s anthrax drug (cont'd)
  • From: James Love <love@cptech.org>
• [e-drug] Rich countries block life-saving drug deal (cont'd)
  • From: Anni Long <along@Oxfam.org.uk>
• [e-drug] Rich countries block life-saving drug deal for poor countries
  • From: Mohga Kamal Smith <msmith@oxfam.org.uk>
• [e-drug] Health and 'commodities'
  • From: Fawzia Rasheed <rasheedf@bluewin.ch>
• [e-drug] Olivieri; need for better patient protection in drug trials
  • From: Barbara Mintzes <bmintzes@telus.net>
October 29, 2001
• [e-drug] Doxycycline becomes D.C.'s anthrax drug (cont'd)
  • From: Kirsten Myhr <myhr@online.no>
• [e-drug] Japan drug formulary
  • From: Elena Romano <eromano@equinox-group.com>
• [e-drug] Comparative drug prices (con'd)
  • From: Bonnie Fundafunda <bfunda@echohealth.org.uk>
• [e-drug] Doxycycline becomes D.C.'s anthrax drug (cont'd)
  • From: James Love <love@cptech.org>
• [e-drug] Anti-hypertensive drug prices
  • From: Douglas Ball <dball@healthnet.zw>
October 28, 2001
• [e-drug] Substandard drugs
  • From: E-drug <e-drug@usa.healthnet.org>
• [e-drug] Doxycycline becomes D.C.'s anthrax drug (cont'd)
  • From: Leo Offerhaus <lo@euronet.nl>
• [e-drug] Doxycycline becomes D.C.'s anthrax drug (cont'd)
  • From: James Love <love@cptech.org>
• [e-drug] Doxycycline becomes D.C.'s anthrax drug (cont'd)
  • From: Leo Offerhaus <lo@euronet.nl>
• [e-drug] WSJ on side effects of Fluoroquinolones
  • From: E-drug <e-drug@usa.healthnet.org>
• [e-drug] Doxycycline becomes D.C.'s anthrax drug of choice
  • From: E-drug <e-drug@usa.healthnet.org>
October 27, 2001
• [e-drug] Dow Jones: WTO and US threat to Bayer patent
  • From: E-drug <e-drug@usa.healthnet.org>
October 26, 2001
• [e-drug] Contents of the Remed Journal, nr 25
  • From: Carinne Bruneton <remed@remed.org>
• [e-drug] LSHTM/GMP fellow/studentships
  • From: E-drug <e-drug@usa.healthnet.org>
• [e-drug] WTO: Lamy must oppose the US goverment strategy
  • From: Olivier Jablonski <jablonski@altern.org>
• [e-drug] Comparative drug prices
  • From: Albert Figueras <afs@icf.uab.es>
• [e-drug] Literature review on anthrax (cont'd)
  • From: John Urquhart <urquhart@ix.netcom.com>
October 25, 2001
• [e-drug] Protecting Pharma Companies from threat of Bio-Terrorism
  • From: Mark Weisbrot <weisbrot@cepr.net>
• [e-drug] Literature review on anthrax (cont'd)
  • From: James Love <love@cptech.org>
• [e-drug] Literature review on anthrax (cont'd)
  • From: Leo Offerhaus <lo@euronet.nl>
• [e-drug] Guardian on Losec patent
  • From: E-drug <e-drug@usa.healthnet.org>
• [e-drug] WSJ on USG/Bayer deal
  • From: E-drug <e-drug@usa.healthnet.org>
• [e-drug] Post-exposure prophylaxis for anthrax (cont'd)
  • From: John Urquhart <urquhart@ix.netcom.com>
October 24, 2001
• [e-drug] Literature review on anthrax (cont'd)
  • From: Kirsten Myhr <myhr@online.no>
• [e-drug] Post-exposure prophylaxis for anthrax (cont'd)
  • From: "Dr.L.Offerhaus" <lo@euronet.nl>
• [e-drug] Injection practices - Uganda study
  • From: Kirsten Myhr <myhr@online.no>
• [e-drug] Medicalisation - A way of life (cont'd)
  • From: K Arnold Chan <kachan@hsph.harvard.edu>
• [e-drug] Post-exposure prophylaxis for anthrax
  • From: Peter Lurie <plurie@citizen.org>
• [e-drug] Medicalisation - Hepatitis B vaccine safety (cont'd)
  • From: Klara Tisocki <ktisocki@healthnet.zw>
• [e-drug] International Conference on Harmonization (cont'd)
  • From: E-drug <e-drug@usa.healthnet.org>
• [e-drug] International Conference on Harmonization
  • From: Wilbert.Bannenberg.wbannenberg@un.org.za
• [e-drug] International Conference on Harmonization (cont'd)
  • From: BUKO Pharma-Kampagne <bukopharma@compuserve.com>
• [e-drug] International Conference on Harmonization
  • From: Wong Wai See <ycwong@brunet.bn>
• [e-drug] Medicilisation - A way of life (cont'd)
  • From: Basim Saab <brsaab@aub.edu.lb>
• [e-drug] % Generics vs branded products (cont'd)
  • From: Kirsten Myhr <myhr@online.no>
• [e-drug] class action on Bayer's ciprofloxacin price
  • From: CBGnetwork@gmx.net
October 23, 2001
• [e-drug] Medicilisation - A way of life (cont'd)
  • From: Steve Toovey <toovey@travelclinic.co.za>
• [e-drug] French drug firm pleads guilty (cont'd)
  • From: Leo Offerhaus <lo@euronet.nl>
• [e-drug] Medicilisation - A way of life (cont'd)
  • From: Carlo Struglia <c.strugli@tiscalinet.it>
• [e-drug] Call for Abstracts - South Asia Pharmaceuticals Conference
  • From: Nancy Blum <nlb@usp.org>
• [e-drug] Medicilisation - A way of life (cont'd)
  • From: Niyada Kiatying-Angsulee <niyada.k@chula.ac.th>
• [e-drug] Cipro and emergency
  • From: "Ellen 't Hoen" <ethoen@hotmail.com>
• [e-drug] Medicilisation - A way of life
  • From: BUKO Pharma-Kampagne <bukopharma@compuserve.com>
• [e-drug] South Asia conference on Drug Quality postponed
  • From: Nancy Blum <nlb@usp.org>
• [e-drug] % Generics vs branded products (cont'd)
  • From: Joel Lexchin <joel.lexchin@utoronto.ca>
• [e-drug] Course Pharmacoeconomics - Evidence, Money & Selection
  • From: David Henry <mddah@mail.newcastle.edu.au>
• [e-drug] Financial Times on patent abuse
  • From: E-drug <e-drug@usa.healthnet.org>
• [e-drug] Literature review on anthrax (cont'd)
  • From: Steve Toovey <toovey@travelclinic.co.za>
October 22, 2001
• [e-drug] Patents and Access to drugs (cont'd)
  • From: Colleen Fuller <cfuller@telus.net>
• [e-drug] French drug firm pleads guilty - pays US$33 Million
  • From: E-drug <e-drug@usa.healthnet.org>
• [e-drug] MSF Pharmacists
  • From: Isabelle Saussereau <isabelle_saussereau@msf.org>
• [e-drug] % Generics vs branded products
  • From: Douglas Defty <douglas.defty@mediclinic.co.za>
• [e-drug] Consumption & quantification of drugs in Nepal
  • From: Dept of Drug Administration <dda@healthnet.org.np>
• [e-drug] Literature review on anthrax prevention and treatment
  • From: Leo Offerhaus <lo@euronet.nl>
• [e-drug] Patents and Access to drugs (cont'd)
  • From: Cecile De Sweemer <btamoh@laotel.com>
October 21, 2001
• [e-drug] Selected Ciprofloxacin prices (cont'd)
  • From: James Love <love@cptech.org>
• [e-drug] Patents and Access to drugs
  • From: Murtada Sesay <msesay@unicef.org>
• [e-drug] Attaran/Gillespie-White and PhRMA patent surveys (cont'd)
  • From: Leo Offerhaus <lo@euronet.nl>
• [e-drug] Selected Ciprofloxacin prices (cont'd)
  • From: Leo Offerhaus <lo@euronet.nl>
• [e-drug] Selected Ciprofloxacin prices
  • From: James Love <love@cptech.org>
October 20, 2001
• [e-drug] Attaran/Gillespie-White and PhRMA patent surveys (cont'd)
  • From: Colleen Fuller <cfuller@telus.net>
• [e-drug] Attaran/Gillespie-White and PhRMA patent surveys (cont'd)
  • From: James Russo <jbrusso@aol.com>
• [e-drug] Attaran/Gillespie-White and PhRMA patent surveys (cont'd)
  • From: Mauro Guarinieri <m.guarinieri@agora.stm.it>
October 19, 2001
• [e-drug] WB/IMF/US shenanigans
  • From: E-drug <e-drug@usa.healthnet.org>
• [e-drug] Canada overrides patent for cipro to treat anthrax
  • From: "Ellen 't Hoen" <ethoen@hotmail.com>
• [e-drug] Health research divide
  • From: E-drug <e-drug@usa.healthnet.org>
• [e-drug] Drugs for Afganistan (cont'd)
  • From: James Russo <jbrusso@aol.com>
October 18, 2001
• [e-drug] Drugs for Afganistan (cont'd)
  • From: George Havens <ghavens@usaid.gov>
• [e-drug] Trizivir patents in Africa
  • From: Mike Palmedo <mpalmedo@cptech.org>
• [e-drug] Attaran/Gillespie-White and PhRMA patent surveys (cont'd)
  • From: Jerome Dumoulin <jerome.dumoulin@upmf-grenoble.fr>
• [e-drug] Drugs for Afganistan
  • From: <educacion@prosalus.es>
• [e-drug] WHO Fact Sheet on Anthrax
  • From: pazvakavambwab@who.int
• [e-drug] Time needed to provide bioequivalence studies (cont'd)
  • From: Esthi Beukes <biodev@mweb.co.za>
October 17, 2001
• [e-drug] Attaran/Gillespie-White and PhRMA patent survey (cont'd)
  • From: Julia Double <julia_double@msf.org>
• [e-drug] Attaran/Gillespie-White and PhRMA patent surveys (cont'd)
  • From: Richard Laing <richardl@bu.edu>
• [e-drug] Attaran/Gillespie-White and PhRMA patent surveys (cont'd)
  • From: E-drug <e-drug@usa.healthnet.org>
• [e-drug] Attaran/Gillespie-White and PhRMA patent surveys (cont'd)
  • From: Dean Baker <dean.baker@worldnet.att.net>
October 16, 2001
• [e-drug] Attaran/Gillespie-White and PhRMA patent surveys
  • From: James.Love, INTERNET:love@cptech.org
• [e-drug] Kofi Annan & 7 drug companies on ARV access
  • From: e-drug@usa.healthnet.org
• [e-drug] NYTimes on Cipro, Cipla, and Bayer
  • From: Asia Russell <asia@critpath.org>
• [e-drug] New website
  • From: Jatinder Singh <jatindersingh@vsnl.com>
October 15, 2001
• [e-drug] Assistance requested
  • From: Dominic Szewczyk <dom@inadeep.com>
• [e-drug] New GDF websites
  • From: Karen Cicerik <cicerik@who.int>
• [e-drug] Short course in sexual and reproductive health research
  • From: Sarah Castle <Sarah.Castle@lshtm.ac.uk>
• [e-drug] Conference pharmacists and AIDS (cont'd)
  • From: Mary Ojoo <mojoo@gerties.org>
October 14, 2001
• [e-drug] Street Price: new VSO report on access to meds
  • From: Ken.Bluestone.ken.bluestone@vso.org.uk
October 12, 2001
• [e-drug] Intellectual property rights and medicines debates
  • From: e-drug@usa.healthnet.org
• [e-drug] WHO Dictionary (cont'd)
  • From: Mary Couper <couperm@who.ch>
• [e-drug] Looking for 'Roche versus Adams'
  • From: Siobhan Morrissey <siobhan_morrissey@hotmail.com>
• [e-drug] Fraud by Abbott and Takeda (cont'd)
  • From: E-drug <e-drug@usa.healthnet.org>
October 11, 2001
• [e-drug] Time needed to provide bioequivalence studies (cont'd)
  • From: James Love <love@cptech.org>
• [e-drug] Time needed to provide bioequivalence studies (cont'd)
  • From: James Love <love@cptech.org>
• [e-drug] WHO Dictionary
  • From: Sana Sukkari <ssukkari@jbmh.com>
• [e-drug] Petition from Oxfam about WTO patent rules
  • From: Els Witschge <els@hai.antenna.nl>
• [e-drug] European Parliament on poverty and access to medicines
  • From: E-drug <e-drug@usa.healthnet.org>
October 10, 2001
• [e-drug] Act Up-Paris on EU's paper at the TRIPS council
  • From: Gaelle Krikorian <galk@compuserve.com>
• [e-drug] Time needed to provide bioequivalence studies (cont'd)
  • From: Esthi Beukes <biodev@mweb.co.za>
October 09, 2001
• [e-drug] Fatal Imbalance: MSF on R&D for neglected diseas
  • From: Mai Do <MDO@paris.msf.org>
• [e-drug] Upcoming course on research methodology
  • From: Jette Norgaard <jen@dfh.dk>
• [e-drug] National Medicines Symposium 2002
  • From: Libby Roughead <Libby.Roughead@unisa.edu.au>
• [e-drug] Conference pharmacists and AIDS developing countries
  • From: Carinne Bruneton <remed@remed.org>
October 08, 2001
• [e-drug] Time needed to provide bioequivalence studies
  • From: James Love <love@cptech.org>
• [e-drug] GSK/BI and CIPLA prices for South Africa
  • From: Ip-health <Ip-health@venice.essential.org>
• [e-drug] Annan Discusses AIDS Drug Discounts with Drug Companies
  • From: e-drug@usa.healthnet.org
• [e-drug] GSK licenses ARVs to South African generic manufacturer
  • From: andy@healthlink.org.za
October 07, 2001
• [e-drug] Short course in community-based health promotion
  • From: John Hubley <john@hubley.co.uk>
• [e-drug] Media advocates support access to treatment campaign
  • From: Omololu Falobi <editor@nigeria-aids.org>
October 06, 2001
• [e-drug] US scientist named as possible head of US FDA
  • From: E-drug <e-drug@usa.healthnet.org>
• [e-drug] Sub-Saharan ARV patents by population and income
  • From: James Love <love@cptech.org>
• [e-drug] Canadian strategy to reduce medical error
  • From: E-drug <e-drug@usa.healthnet.org>
• [e-drug] DTCA for prescription drugs
  • From: E-drug <e-drug@usa.healthnet.org>
October 05, 2001
• [e-drug] Fraud by Abbott and Takeda (cont'd)
  • From: John Urquhart <urquhart@ix.netcom.com>
• [e-drug] New report: Accessing ARVs
  • From: Carmen Perez <carmen.perez@madrid.msf.org>
• [e-drug] Vaccines and vaccination
  • From: Valeria Frighi <valeria.frighi@dtu.ox.ac.uk>
• [e-drug] Fraud by Abbott and Takeda (cont'd)
  • From: Tim Dodd <Cath_and_Tim_Dodd@compuserve.com>
• [e-drug] Subscribing to EDM
  • From: Hilbrand Haak <haakh@usa.healthnet.org>
• [e-drug] Effective treatments for mental illness
  • From: E-drug <e-drug@usa.healthnet.org>
• [e-drug] FDA warns Merck
  • From: E-drug <e-drug@usa.healthnet.org>
• [e-drug] HIV patients in Sub-Saharan countries with ARV patents
  • From: James Love <love@cptech.org>
October 04, 2001
• [e-drug] Fraud by Abbott and Takeda in Medicare and Medicaid
  • From: E-drug <e-drug@usa.healthnet.org>
October 03, 2001
• [e-drug] Newsweek and Direct to Consumer Advertising
  • From: RxUpdate <news@rxpolicy.com>
October 02, 2001
• [e-drug] Essential Drugs Monitor (cont'd)
  • From: Thomas Schwarz <tschwarz@medicusmundi.ch>
• [e-drug] Essential Drugs Monitor subscribing information
  • From: EDM Documentation Centre <edmdoccentre@who.int>
• [e-drug] Table of Contents Essential Drugs Monitor 28&29 - 2000
  • From: EDM Documentation Centre <edmdoccentre@who.int>
• [e-drug] Sleeping sickness prevention
  • From: E-drug <e-drug@usa.healthnet.org>
• [e-drug] Australian Prescriber October 2001
  • From: Susan Reid <susan.reid@HEALTH.GOV.AU>
• [e-drug] Patents in Africa: PhRMA's August 1, 2001 Survey
  • From: James Love <love@cptech.org>
October 01, 2001
• [e-drug] Spamming and viruses
  • From: E-drug <e-drug@usa.healthnet.org>